Merz Therapeutics GmbH

Teijin and Merz Secure Japanese Approval for XEOMIN® in Cervical Dystonia and Blepharospasm

- Japan's MHLW approved XEOMIN® (incobotulinumtoxinA) for cervical dystonia and blepharospasm, marking the fourth and fifth indications for the drug in Japan. - The approval was supported by Phase III trials conducted globally by Merz Therapeutics and locally by Teijin Pharma, including a 48-week Japanese blepharospasm study. - An estimated 28,000 people in Japan suffer from blepharospasm, with tens of thousands more affected by cervical dystonia, representing significant unmet need. - XEOMIN®'s purified formulation, free of complexing proteins, may reduce the risk of neutralizing antibody development during long-term repeat dosing.